Yet the tests are only recommended for those who have symptoms of dementia, and are not definitive on their own. False positives are a concern with these new tests, which detect biomarkers that may indicate the presence of brain proteins linked to the disease. This podcast explores the state of research on the disease and concerns about regulators taking jobs at pharmaceutical and biotech companies, which may influence their approach to approvals. It also dives into an investigation about the data underpinning one experimental Alzheimer’s
